Rigel Pharmaceuticals
RIGL
123 hedge funds and large institutions have $253M invested in Rigel Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 46 increasing their positions, 29 reducing their positions, and 14 closing their positions.
71% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 14
59% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 29
9% more funds holding
Funds holding: 113 → 123 (+10)
7% less capital invested
Capital invested by funds: $272M → $253M (-$19.1M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
77% less call options, than puts
Call options by funds: $70K | Put options by funds: $304K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$5.42M |
| 2 |
Axa
Paris,
France
|
+$5.06M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$4.15M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$2.08M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$9.05M |
| 2 |
SAM
Senzar Asset Management
New York
|
-$3.21M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.3M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$1.27M |
| 5 |
First Manhattan
New York
|
-$561K |
RIGL Hedge Fund Activity: Q2 2015 in Review
123 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2015, worth a combined $253M — down 7% from $272M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new RIGL positions and 14 closed out — a net gain of 10 holders — while 46 added to existing stakes and 29 trimmed.
The largest buyer was TFS Capital, adding an estimated $5.42M. The largest seller was Broadfin Capital, cutting an estimated $9.05M.
- 123 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2015, up from 113 in Q1 2015.
- Funds reported $253M of Rigel Pharmaceuticals stock for Q2 2015, down 7% quarter-over-quarter.
- 24 funds opened new Rigel Pharmaceuticals positions in Q2 2015 and 14 closed out, a net change of +10 holders.
- The largest Rigel Pharmaceuticals buyer in Q2 2015 was TFS Capital, an estimated $5.42M added.
- The largest Rigel Pharmaceuticals seller in Q2 2015 was Broadfin Capital, an estimated $9.05M sold.
Based on aggregated 13F filings for Q2 2015.